TargED Raises 39 Million to Bring Potential Stroke Medicine to Patients

TargED Biopharmaceuticals, a private biotechnology company focused on developing improved treatments for thrombotic diseases, has raised 39 million to accelerate development of its lead compound, a clot-busting compound which binds to a protein present in all forms of thrombosis.

FIRST fund, co-founded by DCVA, has played a key role in the start-up of TargED and also participated in this second investment.

About the investors

The financing was co-led by an international syndicate comprising Andera Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures, and joined by existing investors FIRST, managed by BioGeneration Ventures, Curie Capital and Utrecht Health Seed Fund. TargED will focus development on two initial indications: acquired Thrombotic Thrombocytopenia Purpura (aTTP) and Acute Ischemic Stroke (AIS).

Read the full article here for more information.

Source: Dutch CardioVascular Alliance